Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)

A.M. Algotar; R. Kumar; H.M. Babiker; S.T. Dougherty; C.H. Hsu; H.-H. Chow; T.E. Smith; D.G. Marrero; K.S. Courneya; I. Abraham; J.A. Ligibel; C.A. Thomson

Contemporary Clinical Trials Communications (Mar 2021)

Protocol for a feasibility and early efficacy study of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2)

A.M. Algotar,
R. Kumar,
H.M. Babiker,
S.T. Dougherty,
C.H. Hsu,
H.-H. Chow,
T.E. Smith,
D.G. Marrero,
K.S. Courneya,
I. Abraham,
J.A. Ligibel,
C.A. Thomson

Affiliations

A.M. Algotar: Department of Family and Community Medicine, University of Arizona, USA; The University of Arizona Cancer Center, USA; Corresponding author. University of Arizona, Department of Family and Community Medicine, 655 N Alvernon Way, STE 228, Tucson, AZ, 85711, USA.
R. Kumar: Radiation Oncology, Banner MD Anderson Cancer Center, USA
H.M. Babiker: The University of Arizona Cancer Center, USA; Department of Hematology-Oncology, University of Arizona, USA
S.T. Dougherty: The University of Arizona Cancer Center, USA; Department of Radiation Oncology, University of Arizona, USA
C.H. Hsu: The University of Arizona Cancer Center, USA; Department of Epidemiology and Biostatistics, Mel and Enid College of Public Health, University of Arizona, USA
H.-H. Chow: The University of Arizona Cancer Center, USA
T.E. Smith: Department of Family and Community Medicine, University of Arizona, USA
D.G. Marrero: Department of Health Promotion Science, Mel and Enid College of Public Health, University of Arizona, USA
K.S. Courneya: Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Canada
I. Abraham: Department of Family and Community Medicine, University of Arizona, USA; College of Pharmacy, University of Arizona, USA
J.A. Ligibel: Dana Farber Cancer Institute, Harvard Medical School, USA
C.A. Thomson: The University of Arizona Cancer Center, USA; Department of Health Promotion Science, Mel and Enid College of Public Health, University of Arizona, USA

Journal volume & issue: Vol. 21
p. 100701

Abstract

Read online

Background: Although androgen deprivation therapy (ADT) for prostate cancer demonstrates improved overall and disease-free survival, it is associated with adverse effects such as obesity and metabolic syndrome that increase risk of cardiometabolic disease and diabetes type 2. ADT also leads to fatigue, depression and erectile dysfunction, which reduce quality of life (QoL). Lifestyle modification has shown promise in reducing obesity, metabolic syndrome and diabetes type 2 in other disease types. However, there is a paucity of data regarding the utility of lifestyle modification in men receiving ADT for prostate cancer. Methods: The primary aim of the Comprehensive Lifestyle Improvement Program for Prostate Cancer-2 (CLIPP2) is to test the feasibility of conducting a 24-week lifestyle modification intervention in men on ADT for prostate cancer. Additionally, it will also determine the effect of this intervention on weight loss, cardiometabolic markers (secondary aim and markers of interest: serum glucose, insulin resistance, hemoglobin A1C and lipid panel), and QoL (tertiary aim). The intervention will be delivered weekly via telephone for the first 10 weeks and bi-weekly for the remaining 14 weeks. Questionnaires and serum samples will be collected at baseline, week 12, and week 24. Anthropometric measurements will be collected at baseline, week 6, week 12, week 18 and week 24. Results: We hypothesize that the CLIPP2 intervention will produce a 7% weight loss that will result in improved markers associated with cardiometabolic disease and type 2 diabetes in the study population. Conclusion: Results will provide insight into the role of lifestyle modification in addressing ADT adverse effects as well as provide preliminary data to inform the development of future lifestyle interventions in this area. Trial registration: NCT04228055 Clinicaltrials. gov.

Published in Contemporary Clinical Trials Communications

ISSN: 2451-8654 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General)
Website: https://www.journals.elsevier.com/contemporary-clinical-trials-communications/

About the journal

Abstract

Keywords